TLDR Caterpillar stock fell 3.65% to $419.04 on August 29, 2025. Company raised 2025 tariff cost forecast to $1.5B–$1.8B. Profit margin outlook revised to bottom of guidance range. Analysts cut price targets, citing limited tariff pass-through ability. Strong $37.5B backlog supports long-term business momentum. Caterpillar Inc. (NYSE: CAT) closed at $419.04 on Friday, August 29, [...] The post Caterpillar Inc. ($CAT) Stock: Shares Fall as Tariff Forecast Rises appeared first on CoinCentral.TLDR Caterpillar stock fell 3.65% to $419.04 on August 29, 2025. Company raised 2025 tariff cost forecast to $1.5B–$1.8B. Profit margin outlook revised to bottom of guidance range. Analysts cut price targets, citing limited tariff pass-through ability. Strong $37.5B backlog supports long-term business momentum. Caterpillar Inc. (NYSE: CAT) closed at $419.04 on Friday, August 29, [...] The post Caterpillar Inc. ($CAT) Stock: Shares Fall as Tariff Forecast Rises appeared first on CoinCentral.

Caterpillar Inc. ($CAT) Stock: Shares Fall as Tariff Forecast Rises

TLDR

  • Caterpillar stock fell 3.65% to $419.04 on August 29, 2025.
  • Company raised 2025 tariff cost forecast to $1.5B–$1.8B.
  • Profit margin outlook revised to bottom of guidance range.
  • Analysts cut price targets, citing limited tariff pass-through ability.
  • Strong $37.5B backlog supports long-term business momentum.

Caterpillar Inc. (NYSE: CAT) closed at $419.04 on Friday, August 29, 2025, down 3.65% after warning that tariffs would weigh more heavily on its results.

Caterpillar Inc. (CAT)

The company raised its full-year tariff cost estimate to between $1.5 billion and $1.8 billion, up from its previous outlook of up to $1.5 billion. The update, released ahead of the September quarter, pressured investor sentiment and raised questions about the company’s ability to sustain margins.

Impact on Profitability Outlook

The tariff revision prompted Caterpillar to lower its margin guidance. Management now expects full-year adjusted operating profit margin to land near the bottom of its target range, rather than the top half as previously projected. For the third quarter alone, the company expects tariff costs of $400 million to $500 million, higher than the second quarter’s impact. The revision highlights how shifting U.S. trade policy under the Trump administration is creating uncertainty across the industrial sector.

Market Reaction and Analyst Downgrades

Investors responded to the announcement with a sell-off in CAT shares, reflecting growing concerns about the ability of industrial companies to absorb tariff costs without passing them on to customers. Morgan Stanley analyst Angel Castillo commented that Caterpillar and its peers “have thus far exhibited little to no ability to pass through tariffs,” underscoring a key profitability challenge.

Two analysts cut their price targets following the update. Oppenheimer lowered its target to $480 from $493, while Baird reduced its target to $495 from $500. These revisions reflect caution despite Caterpillar’s resilient demand backdrop.

Long-Term Business Strength Remains

Despite near-term headwinds, some analysts remain optimistic about Caterpillar’s longer-term prospects. The company ended the quarter with a record backlog of $37.5 billion and strong order rates across all divisions. This order book signals continued demand for its heavy equipment, suggesting robust fundamentals even as tariffs pressure margins.

Broader Performance Context

Caterpillar has consistently outperformed the broader market in recent years. As of August 29, 2025, its trailing five-year return was 221.88%, compared to 84.16% for the S&P 500. Its three-year return stood at 130.85% versus the S&P’s 60.28%. Investors are weighing these strong performance metrics against the risks of rising tariffs and lower margin guidance heading into the second half of 2025.

Conclusion

Caterpillar’s revised forecast sent its shares lower as markets digested the increased tariff hit and weaker margin guidance. Analysts were quick to adjust expectations, though the company’s $37.5 billion backlog shows strong underlying demand. For investors, the balance between near-term tariff challenges and long-term growth drivers remains the key consideration.

The post Caterpillar Inc. ($CAT) Stock: Shares Fall as Tariff Forecast Rises appeared first on CoinCentral.

Market Opportunity
Simons Cat Logo
Simons Cat Price(CAT)
$0.000003002
$0.000003002$0.000003002
-2.02%
USD
Simons Cat (CAT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23